Certara (NASDAQ:CERT) Coverage Initiated at TD Cowen

TD Cowen began coverage on shares of Certara (NASDAQ:CERT) in a research report released on Thursday, Marketbeat.com reports. The brokerage issued a buy rating and a $16.00 target price on the stock.

A number of other research analysts have also recently weighed in on the stock. Robert W. Baird dropped their price objective on shares of Certara from $18.00 to $13.00 and set a “neutral” rating for the company in a research note on Tuesday, November 5th. Barclays reduced their target price on shares of Certara from $14.00 to $12.00 and set an “equal weight” rating on the stock in a report on Thursday, November 7th. Five equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. According to data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $15.64.

Certara Trading Up 0.6 %

Shares of CERT stock opened at $12.40 on Thursday. The stock has a market cap of $2.00 billion, a P/E ratio of -62.00, a P/E/G ratio of 9.29 and a beta of 1.57. The company has a quick ratio of 2.86, a current ratio of 2.86 and a debt-to-equity ratio of 0.28. Certara has a fifty-two week low of $9.41 and a fifty-two week high of $19.87. The business has a fifty day simple moving average of $12.43 and a 200-day simple moving average of $11.64.

Institutional Investors Weigh In On Certara

Hedge funds have recently modified their holdings of the stock. Venturi Wealth Management LLC increased its holdings in shares of Certara by 839.1% during the 4th quarter. Venturi Wealth Management LLC now owns 2,808 shares of the company’s stock worth $30,000 after buying an additional 2,509 shares during the last quarter. Wells Fargo & Company MN raised its position in Certara by 48.4% in the fourth quarter. Wells Fargo & Company MN now owns 3,208 shares of the company’s stock valued at $34,000 after purchasing an additional 1,047 shares during the period. Blue Trust Inc. boosted its holdings in Certara by 112.3% in the 3rd quarter. Blue Trust Inc. now owns 3,925 shares of the company’s stock worth $46,000 after acquiring an additional 2,076 shares during the period. Johnson Financial Group Inc. purchased a new position in Certara in the 4th quarter worth approximately $47,000. Finally, KBC Group NV grew its position in Certara by 48.2% in the third quarter. KBC Group NV now owns 4,873 shares of the company’s stock valued at $57,000 after acquiring an additional 1,584 shares in the last quarter. 73.96% of the stock is owned by institutional investors and hedge funds.

About Certara

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.